Value through Innovation25 March 2015

Millions of patients worldwide are affected by RLS, a debilitating neurological condition.

Restless Legs Syndrome (RLS) is a neurological disorder characterised by an uncontrollable urge to move the legs, usually accompanied by unpleasant and sometimes painful sensations in the legs.

Sleep disruption compromises work performance

Restless Legs Syndrome affects up to ten percent of the population worldwide aged between 30 and 79 years and around one-third of sufferers experience symptoms more than twice weekly causing moderate to severe distress.

The motor-restlessness worsens during the evening and night causing difficulty initiating and maintaining sleep. The sleep disruption can lead to excessive daytime sleepiness and compromise work performance. Restless Legs Syndrome also has considerable impact on social activities that require immobility.


Mirapexin®, Sifrol®, Pexola®, Mirapex® (pramipexole)

Indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS).

On 10 November 2006, the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the treatment of moderate to severe primary Restless Legs Syndrome (RLS).

In 2006, Pramipexole, a non-ergot dopamine agonist, has been approved for the symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) in the USA, throughout the European Union and other countries such as Australia, Brazil, Canada, Mexico, followed 2010 by approval in Japan.

Pramipexole (known in Europe under the trade names Mirapexin® and Sifrol® and in the U.S.A. as Mirapex®) is a compound from Boehringer Ingelheim research first approved in 1997 for the treatment of the signs and symptoms of idiopathic Parkinson Disease, as monotherapy or in combination with levodopa.

Criteria for RLS diagnosis

Despite many years of research and increased disease recognition, RLS still remains underdiagnosed or misdiagnosed to this day. RLS may be diagnosed with positive answers to the following criteria, which were developed by participants in the RLS Diagnosis & Epidemiology workshop at the National Institutes of Health in collaboration with members of the International Restless Legs Syndrome Study Group (IRLSSG).

  • Do you have an urge to move your legs, usually accompanied by uncomfortable leg sensations?
  • Do your symptoms begin or worsen during rest or inactivity, such as lying down or sitting?
  • Are your RLS symptoms partially or totally relieved by movement, such as walking or stretching?
  • Are your RLS symptoms worse in the evening or at night, or do they only occur in the evening and at night?


We recognise that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. In addition the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements.

Therefore please check the registration details of this/these product(s) locally in order to get up-to-date information.

Annual Report Website

Annual Report Microsite